pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO
Agios Netherlands
Agios Netherlands B.V.
Agios Netherlands clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CAMBRIDGE, MA, NL
- Founded
- 1978
- Employees
- 20
- Programs
- 45
- Drugs
- 15
- Patents
- 93
Agios Netherlands projects
8 ClinicalTrials.gov programs sponsored by Agios Netherlands.
Agios Netherlands has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AG-348
Agios Netherlands B.V.
Pyruvate Kinase Deficiency
2 trials -
Mitapivat
Agios Netherlands B.V.
Sickle Cell Disease
2 trials -
Mitapivat
Agios Netherlands B.V.
Non-Transfusion-dependent Alpha-Thalassemia
1 trial -
Mitapivat
Agios Netherlands B.V.
Pediatric Pyruvate Kinase Deficiency
2 trials -
Mitapivat Matched Placebo
Agios Netherlands B.V.
Transfusion-dependent Alpha-Thalassemia
1 trial -
Placebo
Agios Netherlands B.V.
Pyruvate Kinase Deficiency
1 trial -
Placebo Matching Mitapivat
Agios Netherlands B.V.
Non-Transfusion-dependent Alpha-Thalassemia
1 trial -
Placebo Matching Mitapivat
Agios Netherlands B.V.
Transfusion-dependent Alpha-Thalassemia
1 trial
Frequently asked questions
How many clinical projects does Agios Netherlands have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.